Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension

Abstract Despite the advancement of targeted therapy for pulmonary arterial hypertension (PAH), poor prognosis remains a reality. Mesenchymal stem cells (MSCs) are one of the most clinically feasible alternative treatment options. We compared the treatment effects of adipose tissue (AD)-, bone marro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Seyeon Oh, Albert Y. Jang, Sehyun Chae, Seungbum Choi, Jeongsik Moon, Minsu Kim, Edda Spiekerkoetter, Roham T. Zamanian, Phillip C. Yang, Daehee Hwang, Kyunghee Byun, Wook-Jin Chung
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d62962afa54f456283ebd67e47698adb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d62962afa54f456283ebd67e47698adb
record_format	dspace
spelling	oai:doaj.org-article:d62962afa54f456283ebd67e47698adb2021-12-02T14:07:47ZComparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension10.1038/s41598-021-81244-12045-2322https://doaj.org/article/d62962afa54f456283ebd67e47698adb2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81244-1https://doaj.org/toc/2045-2322Abstract Despite the advancement of targeted therapy for pulmonary arterial hypertension (PAH), poor prognosis remains a reality. Mesenchymal stem cells (MSCs) are one of the most clinically feasible alternative treatment options. We compared the treatment effects of adipose tissue (AD)-, bone marrow (BD)-, and umbilical cord blood (UCB)-derived MSCs in the rat monocrotaline-induced pulmonary hypertension (PH) model. The greatest improvement in the right ventricular function was observed in the UCB-MSCs treated group. The UCB-MSCs treated group also exhibited the greatest improvement in terms of the largest decrease in the medial wall thickness, perivascular fibrosis, and vascular cell proliferation, as well as the lowest levels of recruitment of innate and adaptive immune cells and associated inflammatory cytokines. Gene expression profiling of lung tissue confirmed that the UCB-MSCs treated group had the most notably attenuated immune and inflammatory profiles. Network analysis further revealed that the UCB-MSCs group had the greatest therapeutic effect in terms of the normalization of all three classical PAH pathways. The intravenous injection of the UCB-MSCs, compared with those of other MSCs, showed superior therapeutic effects in the PH model for the (1) right ventricular function, (2) vascular remodeling, (3) immune/inflammatory profiles, and (4) classical PAH pathways.Seyeon OhAlbert Y. JangSehyun ChaeSeungbum ChoiJeongsik MoonMinsu KimEdda SpiekerkoetterRoham T. ZamanianPhillip C. YangDaehee HwangKyunghee ByunWook-Jin ChungNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Seyeon Oh Albert Y. Jang Sehyun Chae Seungbum Choi Jeongsik Moon Minsu Kim Edda Spiekerkoetter Roham T. Zamanian Phillip C. Yang Daehee Hwang Kyunghee Byun Wook-Jin Chung Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
description	Abstract Despite the advancement of targeted therapy for pulmonary arterial hypertension (PAH), poor prognosis remains a reality. Mesenchymal stem cells (MSCs) are one of the most clinically feasible alternative treatment options. We compared the treatment effects of adipose tissue (AD)-, bone marrow (BD)-, and umbilical cord blood (UCB)-derived MSCs in the rat monocrotaline-induced pulmonary hypertension (PH) model. The greatest improvement in the right ventricular function was observed in the UCB-MSCs treated group. The UCB-MSCs treated group also exhibited the greatest improvement in terms of the largest decrease in the medial wall thickness, perivascular fibrosis, and vascular cell proliferation, as well as the lowest levels of recruitment of innate and adaptive immune cells and associated inflammatory cytokines. Gene expression profiling of lung tissue confirmed that the UCB-MSCs treated group had the most notably attenuated immune and inflammatory profiles. Network analysis further revealed that the UCB-MSCs group had the greatest therapeutic effect in terms of the normalization of all three classical PAH pathways. The intravenous injection of the UCB-MSCs, compared with those of other MSCs, showed superior therapeutic effects in the PH model for the (1) right ventricular function, (2) vascular remodeling, (3) immune/inflammatory profiles, and (4) classical PAH pathways.
format	article
author	Seyeon Oh Albert Y. Jang Sehyun Chae Seungbum Choi Jeongsik Moon Minsu Kim Edda Spiekerkoetter Roham T. Zamanian Phillip C. Yang Daehee Hwang Kyunghee Byun Wook-Jin Chung
author_facet	Seyeon Oh Albert Y. Jang Sehyun Chae Seungbum Choi Jeongsik Moon Minsu Kim Edda Spiekerkoetter Roham T. Zamanian Phillip C. Yang Daehee Hwang Kyunghee Byun Wook-Jin Chung
author_sort	Seyeon Oh
title	Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
title_short	Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
title_full	Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
title_fullStr	Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
title_full_unstemmed	Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
title_sort	comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/d62962afa54f456283ebd67e47698adb
work_keys_str_mv	AT seyeonoh comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension AT albertyjang comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension AT sehyunchae comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension AT seungbumchoi comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension AT jeongsikmoon comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension AT minsukim comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension AT eddaspiekerkoetter comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension AT rohamtzamanian comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension AT phillipcyang comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension AT daeheehwang comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension AT kyungheebyun comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension AT wookjinchung comparativeanalysisontheantiinflammatoryimmuneeffectofmesenchymalstemcelltherapyforthetreatmentofpulmonaryarterialhypertension
_version_	1718391934591959040

Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension

Ejemplares similares